INT101340

Context Info Confidence 0.55 First Reported 2002 Last Reported 2010 Negated 1 Speculated 0 Reported most in Body Documents 3 Total Number 5 Disease Relevance 2.07 Pain Relevance 1.04

plasma membrane (MTNR1A) signal transducer activity (MTNR1A)

Anatomy Link Frequency MT2 1 pineal gland 1 MTNR1A (Homo sapiens)

Pain Link Frequency Relevance Heat antidepressant 45 100.00 depression 45 100.00 5HT 10 100.00 Serotonin 12 97.32 agonist 3 93.38 Inflammation 4 78.16 Dopamine 2 76.08 antagonist 4 56.28 palliative 1 54.00 nud 24 45.76

Disease Link Frequency Relevance Heat Treatment-resistant Depression (TRD) 2 100.00 Gastroesophageal Reflux Disease 147 99.08 Duodenal Ulcer 3 97.86 Sleep Disorders 11 95.34 Toxicity 9 91.24 Peptic Ulcer 6 88.40 Ulcers 18 78.32 INFLAMMATION 7 78.16 Stress 19 77.36 Urological Neuroanatomy 1 76.96

Sentences Mentioned In

Key:

Protein

Mutation

Event

Anatomy

Negation

Speculation

Pain term

Disease term

Ramelteon also is a synthetic analog of melatonin.29 It is a MT1 and MT2 receptor agonist drug currently approved in the United States, Europe, and elsewhere for the treatment of insomnia characterized by difficulty falling sleep.34 Unlike agomelatine, it does not bind to any serotonin receptors and has not been investigated as an antidepressant.24 Mirtazapine and some other antidepressant drugs have 5HT-2C receptor blocking effects.37 Many of the so-called atypical or second generation antipsychotic drugs also have 5HT-2C receptor blocking effects,37 and these drugs are efficacious as augmentation agents when used together with antidepressant drugs for treatment resistant depression.38 The pharmacology of agomelatine, with its combined effects at MT1, MT2, and 5HT-2C receptors, is therefore unique and distinct compared to other antidepressant drugs.

Neg (blocking) Localization (blocking) of MT1 in MT2 associated with antidepressant, depression, treatment-resistant depression (trd), 5ht, agonist, sleep disorders and serotonin

1) Confidence 0.55 Published 2009 Journal Neuropsychiatric Disease and Treatment Section Body Doc Link PMC2785860 Disease Relevance 0.46 Pain Relevance 0.95

Melatonin (MLT) is the main hormone released from the pineal gland and has proved to have physiological antitumor activity.

Localization (released) of Melatonin in pineal gland

2) Confidence 0.07 Published 2002 Journal Support Care Cancer Section Abstract Doc Link 11862501 Disease Relevance 0.20 Pain Relevance 0.09

We used an oral fast release melatonin at a dose of 3 mg/day for 4 and 8 weeks.

Localization (release) of melatonin

3) Confidence 0.02 Published 2010 Journal BMC Gastroenterol Section Body Doc Link PMC2821302 Disease Relevance 0.51 Pain Relevance 0

This observation is in agreement with Klupiñska et al [18] who found that in patients with GERD and recurrent duodenal ulcers, melatonin concentration was lower than in healthy subjects and concluded that high or relatively correct secretion of melatonin is sufficient to prevent peptic changes in esophageal and duodenal mucosa.

Localization (secretion) of melatonin associated with duodenal ulcer and gastroesophageal reflux disease

4) Confidence 0.02 Published 2010 Journal BMC Gastroenterol Section Body Doc Link PMC2821302 Disease Relevance 0.43 Pain Relevance 0

The interests of gstroenterologists mainly focused on studies on melatonin nocturnal secretion.

Localization (secretion) of melatonin

5) Confidence 0.02 Published 2010 Journal BMC Gastroenterol Section Body Doc Link PMC2821302 Disease Relevance 0.46 Pain Relevance 0

General Comments

This test has worked.